Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Clinical trial NCT03628053 · WITHDRAWN
Trial details
- NCT number
- NCT03628053
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-05
- Primary completion
- 2025-10-08
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.